CLINICAL THYROIDOLOGY FOR THE PUBLIC
A publication of the American Thyroid Association
Welcome to another issue of Clinical Thyroidology for the Public. In this journal, we will bring to you the most up-to-date, cutting edge thyroid research. We will be providing summaries of research studies that were discussed in a recent issue of Clinical Thyroidology, a publication of the American Thyroid Association for physicians. These summaries are present in lay language to allow the rapid dissemination of thyroid research to the widest possible audience. This means that you are getting the latest information on thyroid research and treatment almost as soon as your physicians. As always, we are happy to entertain any suggestions to improve Clinical Thyroidology for the Public so let us know what you want to see.
We also provide even faster updates of late-breaking thyroid news through Twitter at @thyroidfriends and on Facebook. Our goal is to provide patients with the tools to be the most informed thyroid patient in the waiting room.
Also check out our friends in the Alliance for Thyroid Patient Education. The Alliance member groups consist of: the American Thyroid Association, Bite Me Cancer, the Graves’ Disease and Thyroid Foundation, the Light of Life Foundation, ThyCa: Thyroid Cancer Survivors Association, Thyroid Cancer Canada and Thyroid Federation International.
In this issue, the studies ask the following questions:
- Should pregnant women be screened for thyroid problems?
- Does pregnancy affect the degree of side effects of antithyroid drugs?
- How common is ANCA-associated vasculitis in patients on antithyroid drugs?
- Is there an association between breast cancer and hyperthyroidism?
- Does metformin protect the bone marrow in diabetic patients treated with radioactive iodine for thyroid cancer?
- Do the variants of papillary thyroid cancer differ in prognosis?
We welcome your feedback and suggestions. Let us know what you want to see in this publication. I hope you find these summaries interesting and informative.
— Alan P. Farwell, MD, FACE